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The Brugada Syndrome (BrS) is considered as a rare Mendelian disorder
with autosomal dominant transmission. BrS is associated with an increased risk
of sudden cardiac death and specific electrocardiographic features consisting of
ST-segment elevation in the right precordial leads. Loss-of-function mutations
in SCN5A, encoding the pore-forming subunit of the cardiac sodium channel
(NaV1.5), are identified in ~20% of patients. However, studies in families har-
boring mutations in SCN5A have demonstrated low disease penetrance and in
some instances absence of the familial SCN5A mutation in some affected mem-
bers. These observations suggest a more complex inheritance model.
To identify common genetic factors modulating disease risk, we conducted
a genome-wide association study on 312 individuals with BrS and 1,115
ancestry-matched controls.
Two genomic loci displayed significant association. Replication testing on
two independent case/control sets from Europe (598/855) and Japan (208/
1016), confirmed both associations and revealed a third locus. The cumulative
effect of the 3 loci on disease susceptibility was large with an odds ratio of
21.5 in the presence of more than 4 risk alleles versus less than 2. 
Two out of three loci had previously been shown to influence ECG
conduction parameters in the general population. The third locus encompasses
a transcription factor which has not previously been implicated in cardiac
electrical function and arrhythmia. Functional studies in mice heterozygous
knock-out for this transcription factor identified differences in expression of
NaV1.5, in addition to differences in conduction of the cardiac electrical
impulse in the right ventricular outflow tract.
Altogether, our findings (1) indicate that common genetic variation may
have a strong impact on predisposition to BrS, and (2) identify a new gene
involved in the pathogenesis of the disease.
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Deletion of QKP1507-1509 amino-acids in SCN5A gene product, the
Nav1.5 voltage-gated Na+ channel, was first discovered in a family with type
3 long QT syndrome (LQT3) and is now associated with a larger phenotypic
spectrum of LQT3, conduction disorder, dilated cardiomyopathy (DCM) and
high incidence of youth sudden death. This mutation does not affect the peak
Na+ current but rather increases the late Na+ current. In order to identify the
mechanism of DCM in these patients, a knock-in mouse model presenting the
delQKP1510-1512 mutation, has been generated.
Four groups of mice were studied: homozygous wild-type (Scn5a+/+),
heterozygous flp deleter (Scn5a+/flp), heterozygous neomycin-ΔQKP
(Scn5a+/neo) and Scn5a+/ΔQKP mice. Scn5a+/ΔQKP mice exhibited high early
mortality with a percentage of death of 50% at the age of 5-6 weeks. Only
35% of Scn5a+/ΔQKP mice survived until week 10 whereas 91% of control
mice. Six-lead ECG recorded on 4 week-old mice anesthetized with isoflu-
rane showed that 6/15 Scn5a+/ΔQKP exhibited numerous ventricular extrasystoles
and/or runs of non-sustained ventricular tachycardia. Six Scn5a+/ΔQKP mice were in
sinus rhythm and showed a prolonged QT interval (QTc=95 ± 12 ms, versus
46 ± 2 ms in controls, n=22). Finally, 3 Scn5a+/ΔQKP mice were in 2:1 atrio-
ventricular block because of highly prolonged QT interval. All control
mice were in sinus rhythm. Sudden cardiac death secondary to ventricular
fibrillation could be recorded in one Scn5a+/ΔQKP mouse, suggesting that
part of early mortality could be attributed to arrhythmias. Alternatively,
mice could also die from heart failure. Indeed, Scn5a+/ǻQKP mice surviving
until the age of 10 weeks showed a heart weight / tibia length ratio of
12.1 ± 3.4 (n=4) versus 7.5 ± 0.5 in control mice (n=14, p< 0.05).
This study shows that Scn5a+/ǻQKP mice reproduce the phenotype of the
human mutation carriers, long QT syndrome, heart failure and increased risk
of sudden death at a young age.
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Progressive cardiac conduction defect (PCCD) is one of the most common
cardiac conduction disturbances characterized by progressive alteration of car-
diac conduction through the His-Purkinje system with right or left bundle
branch block and widening of QRS complexes.
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The disease has been first described in the sixties by Lenegre and Lev as a
simple fibrosis process affecting the conduction system. Familial forms of car-
diac conduction disturbance have been reported with an autosomal dominant
inheritance since then. 
Several genes coding for ionic channels have already been described in this
condition: SCN5A, SCN1B and TRPM4. Other genes have been identified in
PCCD forms associated with other cardiac disease such as congenital heart
disease or cardiomyopathy: NKX2.5, TBX5, PRKAG2, LMNA...
A study based on an epidemiological approach has enabled us to identify
four families in the western part of France. In one of them, the exomes of four
patients have been sequenced using the next generation sequencing techno-
logies (Illumina HiSeq). This strategy has allowed us to identify one missense
variant that seems to segregate with the pathology according to first validation
tests.
This family was composed of 49 members (11 affected; 5 PM). The most
frequent abnormal conduction was PB with LAHB (n=5) and LAHB (n=3). In
this family, one patient had a complete AV block. No ECG was recorded
before implantation for one patient. Nine patients presented a first-degree AV
block. On average, age and heart rate were not different between the affected
and non-affected members. There was a significant difference between PR
duration of the affected group and non-affected group (224±28 ms vs 173±19
ms; p<0.0001) and QRS duration (120±16 ms vs 87±10 ms, respectively;
p<0.0001).
The variant is localized in the LMNA gene (c.G1039A; p.E347K). Muta-
tions in that gene are known to cause a wide range of human diseases (more
than 10 different clinical syndromes have been attributed to LMNA mutations)
including conduction system disease associated with dilated cardiomyopathy.
Our study is the first showing LMNA as a potential responsible of isolated
PCCD.
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Long QT syndrome (LQTS) is an inherited syndrome with QT interval pro-
longation, syncope, and risk of sudden death from ventricular fibrillation.
Fourteen candidate genes are implicated, of which KCNQ1 (LQT1), KCNH2
(LQT2) and SCN5A (LQT3) are the major genetic subtypes, accounting for
approximately 80% of all genotyped LQTS patients. We previously reported
transmission ratio distortion (TRD) in European LQTS families, with an
excess of mutation carriers and female predominance suggesting a survival
advantage for affected gametes. To determine whether this phenomenon
depends on LQTS mutations or gene loci, we studied parental and grandpa-
rental origins of alleles transmitted in LQTS and control families and the role
of channel dysfunction in the transmission distortion.
We studied genotyped members from 679 European and Japanese LQTS
families (2748 carriers). We determined grandparental and parental origins of
mutant alleles in 1892 children and 619 grandchildren, and grandparental
origin of normal alleles in healthy children from 44 three-generation control
CEPH families. In families from Europe and Japan, mutant alleles were
significantly more frequently maternal than paternal in origin (61%, 1155 vs.
737 alleles, p<0.001). The ratio of maternal alleles in LQT1 (66%) was signif-
icantly higher than in LQT2 (56%, p<0.001) and LQT3 (57%, p=0.01). Unlike
control families' Mendelian distribution of grandparental alleles, mutant
grandparental LQT1 and LQT2 alleles in grandchildren showed excess
maternal grandmother alleles.
For LQT1, maternal origin mutant alleles bore a significant relationship to
the level of dysfunction (dominant negative 67%, non-dominant 58%,
p<0.03), however for LQT2 or LQT3 this association was not significant. In
conclusion, there is an excess of LQTS mutant alleles of maternal origin, most
pronounced in LQT1, which is homogeneous across ethnic groups. This is not
linked to a locus-specific grandparental origin allele transmission distortion,
but most probably to potassium channel dysfunction.
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KCNQ1 is the α-subunit of a voltage-dependent potassium channel. In
the heart, KCNQ1 forms a channel complex with KCNE1 to generate the
slow component of the delayed rectifier current IKs. Phosphatidylinositol-
4,5-bisphosphate (PIP2) is a cofactor necessary for the activity of KCNQ1
channels. Some Long QT mutations of KCNQ1, including R243H, R539W
and R555C have been shown to decrease KCNQ1 interaction with PIP2. PIP2
sensitivity of these mutants was determined by using the short acyl chains
analog diC8-PIP2. Since then, hERG channels, known to be regulated by
PIP2, have been shown to be insensitive to this analog, suggesting that a
channel affinity for PIP2 and diC8-PIP2 might be quite different. Hence, we
set out to use other approaches to further study the PIP2 affinity of KCNQ1
mutant channels. 
We measured the kinetics of Mg2+– and wortmannin-induced current
rundown in COS-7 cells expressing the WT or mutant channels and used
either currents amplitudes at the end of the depolarizing step or tail-cur-
rents amplitudes as readout. We show that R539W is very peculiar: as
opposed to WT and R555C channels, the R539W channel current is barely
running down when available PIP2 is decreased, either by wortmannin
application in whole-cell, or by magnesium application in inside-out con-
figuration. Consistent with that, the R539W channel is also insensitive to
extracellular osmolarity, known to modulate the channel activity via PIP2.
These results suggest that KCNQ1-R539W mutation shortcuts PIP2 in the
channel open pore stabilization. Structural model prediction suggests that
the introduced tryptophan in R539W interacts with cholesterol. Both
cyclodextrin application (to deplete membrane cholesterol) on R539W and
substitution of R539 by residues other than tryptophan restore channel run-
down, consistent with the supposed tryptophan-cholesterol interaction. We
conclude that the R539W/cholesterol interaction replaces R539/PIP2 inter-
action in the channel open pore stabilization.
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Brugada syndrome (BrS) is characterized by ST-segment elevation in
the right precordial leads and is associated with an increased risk of SCD
from polymorphic ventricular tachyarrhythmia and ventricular fibrillation.
We have recently reported families with BrS and SCN5A mutations where
some affected members do not carry the familial mutation. These findings
suggest the involvement of additional genetic determinants for BrS in affected
families.
We report the identification of 2 distinct gene mutations within a family
presenting a BrS (5 affected individuals), cardiac conduction defects (CCD,
3 affected individuals) and a shortened QT interval (SQT, 4 affected individ-
uals). The first mutation is nonsense and lies within the SCN5A gene, which
codes for the α-subunit of the cardiac Na+ channel NaV1.5. The second muta-
tion is missense and alters the CACNA1C gene, which encodes the α-subunit
CaV1.2 of the L-type cardiac Ca2±channel. The SCN5A mutation strictly seg-
regates with CCD while 4 out of the 5 BrS patients carrying the CACNA1C
variant present with SQT and/or BrS. Patch-clamp studies identified a net
loss-of-function of the CaV1.2 channel in presence of the missense mutation.
In addition, western-blot experiments showed a global expression defect while
increased mobility of CaV1.2 channels on cell surface was revealed by FRAP
experiments. Finally, computer simulations of the 2 mutations recapitulated
patient phenotypes.
This study reports a rare mutation in the CACNA1C gene as causing BrS
and/or SQT interval in a family carrying a stop mutation in the SCN5A gene,
which does not segregate with the BrS. Furthermore one affected family
member does not harbor any mutation among the 12 BrS known genes under-
lying the complexity of the BrS inheritance and the difficulties of the preven-
tion by a pre-symptomatic genetic screening.
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Purpose: Patients with severe aortic stenosis (AS) and paradoxical low
flow (PLF) (indexed stroke volume< 35ml/m2) despite preserved left ventric-
ular ejection fraction >50%, have worse outcome compared to those with AS
but normal flow. Moreover, Prosthesis-Patient Mismatch (PPM) (indexed
prosthetic valve effective orifice area< 0.85cm2/m2) after aortic valve replace-
ment (AVR) is a predictor of higher mortality. However, the impact of PPM
in patients with PLFAS on long-term survival is unknown. Our aim was to
analyze the prevalence and the impact on long-term survival of PPM in
patients with PLFAS. 
Methods: 667 consecutive patients (age 74±8 years, 42% female, AVA
0.69±0.16 cm²) with preserved LVEF who underwent AVR for severe AS at
our institution between 2000 and 2010 were included in this study. Patients
were divided into 4 groups according to the presence/absence of PLF at car-
diac catheterization and presence/absence of PPM following AVR and we
compared short and long-term survival between these groups.
Results: Among the 667 patients, 26% had PLFAS and PPM occurred
in 54% of patients after AVR. Compared to patients with no PLF & no
PPM (36% of the total cohort), those with PLF & PPM (15%) were signif-
icantly older, with more comorbidities. The 30-day mortality did not differ
between the PLF- PPM and no-PLF-no PPM group. However, the 10-yr
survival rate was significantly reduced in the PLF-PPM (37±9%) group
compared to no PLF-no PPM (70±5%; p=0.003). In multivariate analysis
adjusting for all predictors of survival, concomitant presence of PLF &
PPM was an independent predictor of survival (HR= 2.68 95%CI: 1.5-4.4;
p=0.0003) 
Conclusion: In this catheterization-based study, patients with PLF and
PPM have worse outcome when compared to those without these 2 condi-
tions.
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Tramadol, a centrally acting analgesic derived from chemical synthesis, is
introduced into the armamentarium since its 1977. Due to different pharma-
ceutical presentations and analgesic action fast and efficient (step II analgesics
WHO), its use clinic is widespread both oral and parenteral and by locore-
gional. The scale that takes use of tramadol after removal of dextropr-
poxyphéne market is not quite trivial. In our cardiology department, we
observed over a period of 5 months INR disturbances in a population who
received tramadol IVL. This population is a group of 6 patients of average age
46 – 19.5 years including 4 females and 2 males treated with acenocoumarol.
Stopping tramadol subsequently restores its target INR between 2 to 3 or 3 to
4.5 depending on the clinical context of anticoagulation. This restoration is not
immediate but the INR is restored after an average of 5 days. In our study, we
have refuted the hypothesis suggesting that tramadol interfere with the biolog-
ical analysis of PT and INR for the absence of signs of bleeding. This is by
witnesses containing the blood of patients not anticoagulated and receiving
tramadol. The most likely hypothesis is that pharmacokinetic interaction
involving the step of biotransformation and more specifically one that takes
place in the liver microsomes via cytochrome P450
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Hyperhomocysteinemia is an emerging factor in arterial disease, which is
now taken more seriously by specialists. In the elderly, it makes the post-
myocardial recovery precarious and impairs mental functions.
Figure – 10-years survival according to PLF and/or PPM
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 Our study involved elderly patients with cardiovascular disease (CVD),
mean age 68.3 years. None of these patients was taking hormone supple-
ments or multivitamins.A group of people age and sex matched served as
controls.
The study showed that the plasma concentrations of total homocysteine
(Hcy) were significantly higher in coronary patients compared to controls
15.9 (15 – 19.25) vs. 12.4ȝmol / L (10.6 – 12.8). Homocysteine  was more
positively correlated with levels of high-sensitivity CRP: Hs CRP (r=–0705,
p=0.00) and negatively correlated with the activity of HDL thiolactonase,
a minor compound with a homocysteine  thiolactone hydrolase activity
limiting the atherogenic effects of homocysteine. A multivariate ana-
lysis (Hcy; HTase, CT, TG, Apo A/B ; Hs Crp) showed that only trigly-
cerides influenced the severity of coronary artery disease in these patients
(p=0.04).
Hyperhomocysteinemia as well as dyslipidaemia found in elderly CVD
patients can be mastered by a proper diet and a close monitoring of therapeutic
in elderly patients. 
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Diabetics are prone to cardiovascular disease (CVD), in fact, the rate of
death due to heart problems is two to four times higher in people with type 2
diabetes. The common risk factors for the accumulation of cholesterol plaques
on the walls of the arteries (arteriosclerosis), such as hypertension, obesity,
smoking and high blood lipid levels (dyslipidemia), are known to increase the
cardiovascular risk in people with diabetes. However, other factors may also
be involved namely the excess of an amino acid intermediate in the metabo-
lism of methionine: the Homocysteine.
This study involved a total of 53 people grouped in diabetics (n=27,
age=68.3 years) and non-diabetics (n=26, age=68.7ans). 
A significant higher moderate hyperhomocysteinemia was found in the dia-
betic group (15.8 (14.3-17.2) vs 18.5 mmol / L (15.4 – 24.8). P=0.057) asso-
ciated with a significant decreased thiolactonase activity ( HTase: 327.4
(240.3 -406.8) vs. 266.8U / L (162-365.2). p=0.058). Moreover, in the diabetic
group, the plasma homocysteine  levels were negatively correlated with HTase
activity (r=–0.637 p <0.00). Also in the group of non-diabetic patients on
plasma homocysteine  levels were negatively correlated with the HTase
activity(r=0759, p<0.00.) and positively with apolipoprotein B (apo B:
r=0.862 p <0.05).
A binary regression showed that homocysteine is an important cardio-
vascular risk factor in elderly diabetic patients p=0.058 (diet score; WHR; TG,
HDL cholesterol Hcy)
The hyperhomocysteinemia found in diabetics is responsible for macro-
and micro-vascular diseases leading to death and seems to be an important
risk factor in the elderly. As hyperhomocysteinemia can be improved
easily and safely with folic acid, a particular attention should be given to
the screening and the treatment of hyperhomocysteinemia in elderly
patients
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Background: Tumor necrosis factor alpha (TNF-α) is a primary pro-
inflammatory cytokine and has been implicated in cardiovascular disease
pathogenesis. The TNF-α gene may play an important role in coronary heart
disease (CHD) and myocardial infarction (MI) risk. Controversial results
regarding the association of polymorphisms of the TNF-α gene with CHD/MI
have been reported. The aim of this study was to investigate the possible asso-
ciation between the G-308 A (rs1800629), the C-863 A (rs1800630) and the
T–1031 C (rs1799964) polymorphisms in the promoter region of the TNF-α
gene and MI in a sample of the Tunisian male population. In addition, we also
examined the association of TNF-α gene haplotypes with MI in Tunisian male
subjects.
Methods: A total of 276 unrelated patients with MI and 287 controls were
included in this study. The SNPs of the TNF-α gene were determined by poly-
merase chain reaction-restriction fragment length polymorphism (PCR-RFLP)
analysis. The genotype distribution was in Hardy –Weinberg equilibrium for
all variants. 
Results: The genotype distribution and the relative allelic frequencies for
the 3 variants investigated were not significantly different between MI and
control subjects (P=NS). Moreover, the odds ratio for MI associated with the
–308A (OR=1.06, 95% CI 0.78 – 1.44), –863A (OR=1.22, 95% CI 0.83 – 1.81)
and –1031C (OR=1.06, 95% CI 0.81 – 1.39) variants failed to reach statistical
significance. Haplotype-based analysis also failed to reveal an association
between MI and investigated variants. 
Conclusion: Our data suggested that these polymorphisms of the TNF-α
gene are unlikely to be major factor in the susceptibility to MI in the Tunisian
population studied.
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The effect of apolipoprotein E and CYP3A4 polymorphisms on the
response to lipid-lowering treatment with atorvastatin.
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Background: Statins are one of the most commonly prescribed classes of
drug worldwide and therapy is highly effective in reducing low-density lipo-
protein cholesterol (LDLc) levels and cardiovascular events. Inspite of these
recognized benefits, there is large variability in clinical response to statin
treatment. This may be due to the interaction of environmental and genetic
factors that affect drug bioavailability, receptor function or ligand structure.
Our objective was to assess the effect of 2 polymorphysms in apolipoprotein
E (ApoE) and CYP3A4 genes on response to atorvastatin.
Methods: Our study included 60 patients, hospitalized for ACS. DNA was
extracted from leucocytes and analyzed by the PCR-RFLP protocol. Lipid pro-
files and calculation of LDLc were performed before and 8 weeks after initi-
ation of atorvastatin 40mg/day. We proposed a definition of resistance to
atorvastatin (reduction in LDLc<20%) and then looked for correlations
between clinical factors, polymorphisms of CYP3A4 and Apo E and the lipid
response to atorvastatin 40mg/day.
Results: The average baseline LDLc was 1.13g/l ±0.4; baseline LDL
cholesterol was lower in E4 allele carriers (p=0.06) and G allele carriers
(p<0.01). At the end of the follow up period, the absolute reduction of LDLc was
–0.35g/l ±0.43 and the relative reduction of –23.90%±31.68. Resistance to
atorvastatin was noted in 37.9% of patients. In univariate analysis, this
resistance was inversely correlated with baseline LDLc(p<0.01). The G
allele (CYP3A4*1G) was associated with poor response to atorvastatin
(p<0.01) and the E4 allele (ApoE) was associated with a higher risk of
resistance (p=0.01). In multivariate analysis the studied polymorphisms
were not independently associated with response to atorvastatin and only
the baseline LDLc was predictive of the response and of the resistance to
atorvastatin.
Conclusion: This study objectified, in univariate analysis, a correlation
between low baseline LDLc, poor response to atorvastatin and E4 and G
alleles. Multivariate analysis, however, calls into question the interest of
genetic markers compared to the only baseline rate of LDLc to predict the
resistance to atorvastatin.
© Elsevier Masson SAS. All rights reserved.
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Corticotropin-releasing hormone (CRH) is involved in cardiac energy
homeostasis
Theodora Tzanavari, Emilia Varela, Katia P. Karalis, Dennis V. Cokkinos
BRFAA, Athens, Grèce
Background: The response of various systems to stressful stimuli is influ-
enced by the HPA axis. We have previously demonstrated that the stress hor-
mone corticotropin (CRH), the hypothalamic component of the axis with
various peripheral actions, contributes to cardiac function in basal and stressful
(LPS-induced) conditions; with Crh–/– mice exhibiting compromised myocar-
dial function at basal levels, which further deteriorates upon LPS administration.
In this study, given the emerging evidence on the metabolic dysregulation
underlying cardiovascular dysfunction and associated disease development, we
investigated whether the effects of Crh deficiency are due to metabolic changes. 
Methods: Crh+/+ and Crh–/– mice±LPS (n=10/group) were treated with
bezafibrate and metformin. Mice were subjected to 2D M-mode echocardio-
graphy. Markers were analyzed by qPCR and western blotting. 
Results: Compared to Crh+/+ mice, Crh–/– had reduced expression of
genes involved in lipid and glucose utilization, reminiscent of starving myo-
cardium. These included the reduced expression of the β-oxidation markers
ACO (80%) and Hadha (52%) and the glycolysis marker HexokinaseII (82%).
In addition, PPARα (37%) and its target genes, as well as PPARγ (62%) and
its co-activator PGC1α (66%) were downregulated in Crh–/–, as well as
AMPKα2 (58%). LPS administration led to further decrease in the expression
levels of these markers. Administration of the PPAR agonist bezafibrate in
Crh–/– mice partially ameliorated the detrimental effects of LPS administra-
tion. Metformin treatment of Crh–/– mice prior to and after LPS led to further
improvement of the LPS effects and significant extension of their survival
time, via upregulation of AMPK and ACC. 
Conclusion: Our results indicate a novel role for CRH in cardiac function
via impaired myocardium FA metabolism. The specific factors mediating the
effects of CRH on cardiomyocytes and the relevance of these findings to
human conditions are under investigation. 
254
Intratissular procoagulant microparticles do not contribute to
enhanced thrombotic status in diabetes mellitus patients. Role in
intraplaque hemorrhage and vulnerability?
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Ohlmann (4), Florence Toti (5), Christian Gachet (3), Olivier Morel (1)
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Background: Recent data have suggested the central importance of the
tissue factor-microparticle-mediated pathway in diabetic thrombophilia and
cardiovascular complications. Advanced human atherosclerotic plaques
contain large amounts of microparticles (MPs) and MPs isolated from human
atherosclerotic lesions are highly thrombogenic. In the present study, we
sought to investigate whether intra tissular procoagulant MPs trapped with
carotid atheromatous plaque contribute to an enhanced thrombotic propensity
in type 2 diabetes mellitus (T2DM) patients 
Patients, materiel and methods: 77 consecutive patients undergoing carotid
artery endarterectomy were prospectively enrolled. The population was split in
4 sub-groups according to the diabetes status (T2DM, NTDM) and to the clin-
ical presentation (symptomatic (SYM) or not (NSYM). MPs were isolated from
the atherosclerotic plaque using serial centrifugation. MPs prothrombinase and
tissue factor activities, cellular origins were determined. Plaque thrombogenicity
using chamber perfusion model at various shear stress was determined.
Results: Regardless of the diabetic status, high concentrations of procoagulant
MPs mainly of leukocyte and endothelium origins could be detected within the
plaque. Prothrombinase and tissue factor activities harbored by MPs appeared to
be in the same range in plaques obtained from T2DM or NT2DM patients. Like-
wise, chamber perfusion data failed to evidence enhanced thrombogenic status
associated with diabetic plaque. Conversely, high levels of platelet and erythro-
cytes MPs could be evidenced within the plaque of SYM T2DM patients.
Conclusion: The present study did not substantiate the view of a specific
increased of thrombotic potential displayed by MPs within carotid atheroscle-
rotic plaque in diabetes mellitus patients. Conversely, high levels of platelet
and erythrocytes MPs, appear to be a characteristic feature of the diabetic
vulnerable plaque. Whereas these MPs are solely a marker of intra plaque
haemorrhage or act as true effector involved in matric proteolysis and angio-
genesis remain to be established.
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Effects of eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA) on lamb fetus pulmonary circulation 
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Persistant pulmonary hypertension is responsible for significant morbidity
and mortality in neonates. We showed that, compared with Intralipid, the
Omegaven® (including EPA and DHA) has pulmonary vasodilator properties
during the perinatal life. 
Objectives: To determine the active agent. We studied the circulatory
effects of EPA and DHA in model of lamb fetus and in vitro in isolated vas-
cular rings to clarify the mechanism of action.
Methods: sheep were operated at 128 days of gestation, catheters were
placed in the systemic and pulmonary circulation, Doppler probe around the
left pulmonary artery (LPA). Pulmonary artery pressure (PAP) and the LPA
flow (LPAF) were measured during the injection of EPA or DHA for
120 minutes, allowing calculation of pulmonary vascular resistance (PVR).
Blood gases were taken before and after injection of EPA or DHA. In vitro
experiments studied effect-dose of EPA in isolated vascular rings incubated
with increasing concentrations after vasoconstriction by agonist of Throm-
boxane A2. Vascular rings were separated into two groups E+ (intact endothe-
lium) and E- (damaged endothelium), according to response to acetylcholine.
Results: EPA induced significant and prolonged drop of 22% in pulmonary
vascular resistance (n=8, p <0.001). DHA did not alter LPAF, or PVR. Heart
rate, PAP and arterial blood gases did not change during experiments. Injection
of ethanol, their solvent, had no significant effect on LPAF and RVP.
Incubation of EPA caused a maximum relaxation of 60% in group E +
(n=7), whereas vessels tone did not change in group E- (n=5, p<0.001).
Response to sodium nitroprusside was not different between 2 groups, indi-
cating integrity of smooth muscle. 
Conclusion: EPA induces a pulmonary vasorelaxation in lamb fetus
without adverse effects. This effect is endothelium- and dose-dependent.
These results suggest that EPA should be used in clinical situations associated
with pulmonary hypertension in the newborn
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Association of homocysteine thiolactonase activity and PON1 poly-
morphisms with the severity of acute coronary syndrome
Mohamed Hammami (1), Ndia Koubaa (1), Sonia Hammami (2), Amel
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Introduction: Excess of total homocysteine (tHcy) and decrease of thio-
lactonase activities (HTase) have been proposed as risk factors for coronary
artery diseases (CAD).
© Elsevier Masson SAS. All rights reserved.
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Objectives: We evaluated the relationship of tHcy and HTase with paraox-
onase 1 (PON1) gene polymorphism according to CAD severity.
Design and methods: 118 healthy volunteers and 91 CAD patients were
compared.
Results: Serum levels of tHcy and oxidized LDL (ox-LDL) increased
significantly by 26% and 48% in CAD patients and were associated with
significantly lower levels of HDL cholesterol (p= 0.02) and 42% of
decrease in HTase activities (pb0.05). In these patients the HTase activity
was negatively associated with tHcy and Hs CRP levels (r=−0.622, p=0.00
and r=−0.355, p=0.007 respectively) but positively associated with apoB
and triglyceride levels (r=0.35, p=0.042 and r=0.308, p=0.003 res-
pectively). HTase activity decreased inversely to the number of affected
vessels and according to PON1 polymorphism. PON1 Q192R RR and
PON1 L55M MM genotypes were associated with higher HTase activities.
Only PON1 L55M (MM) genotype frequency was significantly higher in
CAD patients than in controls (Pb0.05), while its frequency was similar
between the two subgroups according to CAD severity. In a multivariate
analysis, tHcy levels were the only independent factor affecting the severity
of cardiovascular disease (p= 0.029).
Conclusions: High tHcy levels are associated with the severity of cardio-
vascular disease and may be partly explained by the diminished HTase acti-
vities in these patients.
Keywords: Homocysteine; Thiolactonase; Coronary artery disease;
Severity; Ox-LDL; Paraoxonase 1 polymorphism
